| Ytd | 79.55% | |
| 1y | 36.88% |
| Open | 5.56 | Prev Close | 5.46 | Low | 5.16 | High | 5.56 | Mkt Cap | 100.24M |
| Vol | 5.93K | Avg Vol | 51.66K | EPS | -0.70 | P/E | N/A | Forward P/E | -27.22 |
| Beta | 0.68 | Short Ratio | 0.04 | Inst. Own | 1.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 4.49 | 200-d Avg | 3.89 | 1yr Est | 8.00 |
Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:AT
Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday's session as the biotechnolog
Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, wh
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design
"These data continue to strengthen the evidence that ATH434 has the potential to be the first di
– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disea
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disea
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the plann
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in
This second Type C Meeting builds on Alterity's recent regulatory interactions with the FDA and
MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS
NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report)
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) was the recipient of
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key ele
Alterity Therapeutics (NASDAQ: ATHE) outlined its development strategy for lead drug candidate ATH43
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapi
Athira Pharma (NASDAQ: ATHA - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Re
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights P
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) was the recipient of
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biot
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New an
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
Alterity Therapeutics Limited (‘ATH'): ASX Aware LetterASX refers to the following:A.ATH's a
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurol
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidanc
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints ––
Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals wit
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot